<DOC>
	<DOC>NCT00499967</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.</brief_summary>
	<brief_title>Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>Have 2 or more genital warts of prespecified sizes on external surfaces of the body. If HIV positive, have HIV RNA &lt; 400 copies/mL, CD4 count of â‰¥ 400 cells/mm3, and be taking a triple combination antiviral medication regimen Prior genital wart treatment within 8 weeks Pregnancy or breastfeeding Presence of broken or nonintact skin near the wart site or other skin disease at the wart site (e.g., herpes genitalis) Treatment with systemic steroids, systemic immunomodulators, immunosuppressants, or chemotherapeutic agents within 3 months Current or prior diagnosis of Bowenoid papulosis, cancer, or precancerous tissue in the genital area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>genital warts</keyword>
	<keyword>venereal warts</keyword>
	<keyword>human papilloma virus</keyword>
</DOC>